Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up
Information source: Helsinki University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atopic Dermatitis
Intervention: Histamine provocation (Procedure); Skin prick tests (Procedure); Serum IgE blood testing (Procedure); Mantoux-testing (Procedure)
Phase: N/A
Status: Completed
Sponsored by: Helsinki University Official(s) and/or principal investigator(s): Sakari Reitamo, MD, PhD, Principal Investigator, Affiliation: Skin- and Allergy Hospital, Dep. of Dermatology
Summary
The investigators will contact 64 patients with atopic dermatitis (AD) who participated in a
long-term tacrolimus ointment trial in Helsinki 10 years ago, and ask them to participate in
this follow-up study. The investigators will do the same tests as 10 years ago, i. e.
bronchial hyperreactivity, skin prick tests, serum-IgE, Mantoux-test (2 TU), and
questionnaires about asthma and allergic rhinitis symptoms. The investigators also collect
data about their AD medication during the last 10 years.
The investigators hypothesis is that when the skin condition improves in patients with AD
the brochial hyperreactivity improves. The investigators also want to study whether
different treatments play a role in the development or resolution of bronchial
hyperreactivity.
Clinical Details
Official title: Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up
Study design: Observational Model: Cohort
Primary outcome: Bronchial hyperreactivity
Secondary outcome: Skin prick testsSerum-IgE Mantoux-test
Detailed description:
We will by letters and telephone contact all patients (n=64) who fulfill the inclusion
criteria for this study.
The testing in the study (bronchial hyperreactivity, skin prick testing, serum IgE) is
cross-sectional, but we retrospectively collect data from the last 10 years about the skin
condition and medication for atopic diseases.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient has participated in the FG-506-06-21 study in Helsinki
- Patient was tested for bronchial hyperreactivity in the years 1998-2000
- Patient gives signed informed consent to participate in this study
Locations and Contacts
Skin- and Allergy Hospital, Department of Dermatology, Helsinki 00250, Finland
Additional Information
Related publications: Virtanen H, Remitz A, Malmberg P, Rytilä P, Metso T, Haahtela T, Reitamo S. Topical tacrolimus in the treatment of atopic dermatitis--does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol. 2007 Dec;120(6):1464-6. Epub 2007 Oct 1.
Starting date: November 2008
Last updated: April 19, 2011
|